Summary
PROJECT SUMMARY The incidence of cutaneous melanoma is rising. While small molecule targeted inhibitors and immune checkpoint antibodies have increased long-term survival in advanced-stage cutaneous melanoma, many patients still do not benefit and regimens are associated with high toxicity. We are studying the determinants of treatment response and mechanisms of resistance in melanoma. From our studies, we aim to generate pre- clinical data for new combinations that delay/prevent the onset of acquired resistance while minimizing patient toxicities in order to improve patient survival and quali
